A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia

Psychopharmacology

Volumn 231, Issue 3, 2014, Pages 533-542

  Farokhnia, Mehdi ^a   Sabzabadi, Maryam ^a   Pourmahmoud, Hossein ^b   Khodaie Ardakani, Mohammad Reza ^b   Hosseini, Seyed Mohammad Reza ^a   Yekehtaz, Habibeh ^a   Tabrizi, Mina ^c   Rezaei, Farzin ^d   Salehi, Bahman ^e   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trial; Glutamate; Negative symptoms; PANSS; Riluzole; Schizophrenia

Indexed keywords

PLACEBO; RILUZOLE; RISPERIDONE; AMINO ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT;

ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEGATIVE SYNDROME; OUTCOMES RESEARCH; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; CHRONIC DISEASE; DRUG COMBINATION; MALE; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PSYCHIATRIC STATUS RATING SCALES; RILUZOLE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84892814107     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3261-z     Document Type: Article

References (49)

1. Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Tabrizi M, Rezazadeh SA (2011) Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology (Berl) 213:809-815
2. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57:270-276
3. Arundine M, Tymianski M (2003) Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell calcium 34:325-337
4. Chouinard G, Margolese HC (2005) Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76:247-265
5. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58:424-428
6. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:365-384
7. Crow TJ (1981) Positive and negative schizophrenia symptoms and the role of dopamine. Br J Psychiatry 139:251-254
8. Danysz W, Parsons CG (2002) Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res 4:119-126
9. Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47:S233-S241
10. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, Falke C, Zarate CA Jr, Manji HK (2007) The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32:793-802
11. Durany N, Thome J (2004) Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 19:326-337
12. Fenton WS, McGlashan TH (1991) Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 48:978-986
13. Frizzo ME, Dall'Onder LP, Dalcin KB, Souza DO (2004) Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 24:123-128
14. Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz H, Ashrafi M, Hassanzadeh E, Akhondzadeh S (2013) Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled. Randomized Trial, Paediatr Drugs. doi: 10.1111/bdi.12108
15. Gilgun-Sherki Y, Panet H, Melamed E, Offen D (2003) Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res 989:196-204
16. Grant P, Lougee L, Hirschtritt M, Swedo SE (2007) An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 17:761-767
17. Grant P, Song JY, Swedo SE (2010) Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 20:309-315
18. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
19. Hanson E, Healey K, Wolf D, Kohler C (2010) Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep 12:563-571
20. Javitt DC (2012) Twenty-five years of glutamate in schizophrenia: are we there yet? Schizophr Bull 38:911-913
21. Jedema HP, Moghaddam B (1994) Glutamatergic control of dopamine release during stress in the rat prefrontal cortex. J Neurochem 63:785-788
22. Jedema HP, Moghddam B (1996) Characterization of excitatory amino acid modulation of dopamine release in the prefrontal cortex of conscious rats. J Neurochem 66:1448-1453
23. Jentsch JD, Redmond DE, Jr., Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277: 953-955.
24. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225
25. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
26. Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S (2013) Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res 47:472-478
27. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169:215-233
28. Lacomblez L, Bensimon G, Leigh PN, Debove C, Bejuit R, Truffinet P, Meininger V (2002) Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 3:23-29
29. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A (2005) Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 27 Suppl A: S16-S24
30. Lourenco Da Silva A, Hoffmann A, Dietrich MO, Dall'Igna OP, Souza DO, Lara DR (2003) Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 48:27-30
31. Martin D, Thompson MA, Nadler JV (1993) The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 250:473-476
32. Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM (2005) Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162:2379-2381
33. Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane database of systematic reviews (Online) 3: CD001447.
34. Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Kuno S (2001) Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 310:117-120
35. Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S (2013) Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 27:57-65
36. Moghaddam B (2004) Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 174:39-44
37. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal Neurosci 17:2921-2927
38. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352.
39. Muller N, Schwarz MJ (2010) Immune System and Schizophrenia. Curr Immunol Rev 6:213-220
40. Murphy BP, Chung YC, Park TW, McGorry PD (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 88:5-25
41. Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Rezaei F, Salehi B, Ashrafi M, Yekehtaz H, Tabrizi M, Akhondzadeh S (2013) A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology (Berl) 228(4):595-602
42. Paz RD, Tardito S, Atzori M, Tseng KY (2008) Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur neuropsychopharmacol 18:773-786
43. Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S (2013) Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 33:336-342
44. Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH (2007) Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61:822-825
45. Stone JM, Morrison PD, Pilowsky LS (2007) Glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review. J Psychopharmacol 21:440-452
46. Wang SJ, Wang KY, Wang WC (2004) Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 125:191-201
47. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161:171-174
48. Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57:430-432
49. Zarate CA, Manji HK (2008) Riluzole in psychiatry: a systematic review of the literature. Expert Opin Drug Metab Toxicol 4:1223-1234